Anteris Secures CMS Reimbursement for Pivotal Heart Valve Trial
Event summary
- Anteris Technologies secured U.S. Medicare reimbursement eligibility for the PARADIGM Trial, a pivotal study evaluating its DurAVR transcatheter heart valve.
- The trial utilizes a Coverage with Evidence Development (CED) model, linking reimbursement to clinical evidence generation.
- The PARADIGM Trial will enroll approximately 1,000 patients in a randomized controlled trial.
- The trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, stroke, and cardiovascular hospitalization at one year post-procedure.
- Anteris’ DurAVR THV uses ADAPT® tissue, an FDA-cleared technology used in over 55,000 patients globally.
The big picture
Securing CMS reimbursement for a pivotal trial is a critical step for medical device companies seeking market access in the U.S., particularly for innovative technologies like Anteris’ DurAVR. The CED model, while providing a pathway to reimbursement, also creates a performance-based risk. This trial's outcome will directly impact Anteris' ability to challenge established players in the $6 billion+ TAVR market and validate its ADAPT tissue technology.
What we're watching
- Trial Execution
- The success of the PARADIGM Trial hinges on timely patient enrollment and data collection; delays could significantly impact Anteris’ commercialization timeline and investor confidence.
- Reimbursement Risk
- While the initial reimbursement approval is positive, CMS’s ongoing assessment of the trial’s data will determine continued coverage, creating a potential risk if results are unfavorable.
- Competitive Landscape
- The PARADIGM Trial’s head-to-head comparison against commercially available TAVRs will reveal DurAVR’s relative performance and influence its adoption rate against established competitors.
Related topics